Table 1.
Demographic profile of participants by dose cohort
|
Single ascending dose study |
Volunteer infection study |
|||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Placebo (N=17) | 50 mg (N=6) | 100 mg (N=6) | 200 mg (N=6) | 400 mg (N=6) | 600 mg (N=6) | 1000 mg (N=6) | 1250 mg (N=6) | 1800 mg (N=6) | 2100 mg (N=1) | 150 mg (N=6) | 400 mg (N=8) | 800 mg (N=8) | ||
| Age, years | 28 (10·2) | 28 (6·4) | 31 (7·3) | 30 (6·7) | 27 (13·5) | 25 (10·1) | 28 (10·9) | 26 (7·0) | 30 (9·8) | 43 (NC) | 30 (11·2) | 25 (5·9) | 30 (9·4) | |
| Race or ethnicity | ||||||||||||||
| White | 13 (76%) | 4 (67%) | 4 (67%) | 6 (100%) | 5 (83%) | 6 (100%) | 2 (33%) | 5 (83%) | 4 (67%) | 1 (100%) | 4 (67%) | 4 (50%) | 8 (100%) | |
| Asian | 2 (12%) | 0 | 0 | 0 | 0 | 0 | 3 (50%) | 0 | 1 (17%) | 0 | 1 (17%) | 1 (13%) | 0 | |
| Black or African American | 1 (6%) | 0 | 1 (17%) | 0 | 0 | 0 | 0 | 0 | 1 (17%) | 0 | 0 | 1 (13%) | 0 | |
| American Indian or Alaska Native | 0 | 1 (17%) | 1 (17%) | 0 | 1 (17%) | 0 | 0 | 0 | 0 | 0 | 1 (17%) | 2 (25%) | 0 | |
| Native Hawaiian or Other Pacific Islander | 0 | 1 (17%) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Mixed | 1 (6%) | 0 | 0 | 0 | 0 | 0 | 1 (17%) | 1 (17%) | 0 | 0 | 0 | 0 | 0 | |
| Body-mass index, kg/m2 | 24·2 (2·4) | 24·6 (3·2) | 24·4 (2·9) | 26·2 (1·8) | 22·0 (2·5) | 25·2 (2·6) | 24·6 (3·7) | 23·3 (2·6) | 25·7 (2·5) | 28·7 (NC) | 22·4 (2·8) | 23·2 (2·9) | 25·3 (2·7) | |
| Height, cm | 178·0 (6·8) | 183·0 (10·4) | 176·0 (7·7) | 178·0 (6·7) | 178·0 (3·9) | 178·0 (7·8) | 179·0 (6·8) | 181·0 (4·9) | 183·0 (9·3) | 171·0 (NC) | 175·0 (4·7) | 176·0 (9·5) | 181·0 (6·3) | |
| Weight, kg | 76·4 (10·4) | 82·4 (14·9) | 75·9 (10·6) | 83·4 (9·7) | 69·9 (9·9) | 80·0 (10·4) | 78·3 (12·7) | 75·8 (7·6) | 86·1 (9·4) | 83·9 (NC) | 68·8 (11·6) | 72·7 (14·7) | 83·4 (11·0) | |
Data are mean (SD) or n (%). 100% of participants in all groups were male. NC=not calculable.